Siddhant P. Bhoir

Targeting O6-methylguanine-DNA methyltransferase deficiency in preclinical models of extracranial human cancers with a tumor-selective DNA modifying agent

Temozolomide (TMZ) is an established therapy for gliomas with silencing of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) but is hindered by the frequent development of resistance via loss of mismatch repair (MMR) proteins. To overcome this resistance, a novel 2-fluoroethylating agent, KL-50, was...